<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04693884</url>
  </required_header>
  <id_info>
    <org_study_id>UOG-HPL-CAN (REB# 18-11-013)</org_study_id>
    <nct_id>NCT04693884</nct_id>
  </id_info>
  <brief_title>Cannabis Inhalation: Effects on Cardiovascular Function During Rest and Exercise</brief_title>
  <official_title>The Influence of Cannabis Inhalation During Exercise on Cardiovascular Health and Function: Exploring the Optimal Balance of Cannabinoids and Mode of Administration to Decrease Risk and Maximize Benefits</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jamie Burr</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Guelph</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This two-phase project seeks to examine the cardiovascular response to consumption of&#xD;
      cannabis variants of different cannabinoid composition through different methods (smoking vs.&#xD;
      vaporizing), at rest and during aerobic exercise. Multiple measures that have been shown to&#xD;
      predict risk factors for chronic-disease and negative health outcomes will be assessed&#xD;
      following cannabis consumption at rest or in combination with exercise. These techniques will&#xD;
      examine arterial stiffness, vascular function, and cardiac function. In phase I and II,&#xD;
      subjects will visit the lab on 6 different occasions; with 1 visit acting as an introductory&#xD;
      visit, 1 as an exercise control visit, 2 as resting cannabis visits, and 2 as cannabis +&#xD;
      exercise visits. Cannabis used in phase I of this study will consist of approximately 10%&#xD;
      THC. On all visits, pulse wave velocity, flow mediated dilation, and echocardiography&#xD;
      measures will be performed following cannabis consumption by smoking or vaporizing, and&#xD;
      cannabis consumption by smoking or vaporizing followed by 20 minutes of exercise on a cycle&#xD;
      ergometer. Phase II of the study will implore a similar design. In favor of altering method&#xD;
      of consumption, in all visits cannabis will be consumed by vaporization and will be either a&#xD;
      high cannabidiol (CBD: (~10%)) and low delta-9-tetrahydrocannabinol (THC: (&lt;1%)), or a high&#xD;
      THC (~10%) and low CBD (&lt;1%) variant.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Aortic Stiffness From Baseline Following Cannabis Consumption</measure>
    <time_frame>Baseline, Post-Intervention (&lt;2 Hours)</time_frame>
    <description>Assessed via carotid-femoral pulse wave velocity (PWV)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Brachial Artery Vascular Function From Baseline Following Cannabis Consumption</measure>
    <time_frame>Baseline, Post-Intervention (&lt;2 Hours)</time_frame>
    <description>Assessed via brachial artery flow mediated dilation (FMD)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Sympathetic Nervous System Activity From Baseline Following Cannabis Consumption</measure>
    <time_frame>Baseline, Post-Intervention (&lt;2 Hours)</time_frame>
    <description>Assessed via microneurographic recordings of the peroneal nerve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Cardiac Function From Baseline Following Cannabis Consumption</measure>
    <time_frame>Baseline, Post-Intervention (&lt;2 Hours)</time_frame>
    <description>Measured by echocardiography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exercise Capacity</measure>
    <time_frame>Baseline, Post-Intervention (&lt;2 Hours)</time_frame>
    <description>Assessed by maximal average power attainable during 20 minutes of continuous cycling exercise</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>Baseline, Post-Intervention (&lt;2 Hours)</time_frame>
    <description>Measured at rest and during exercise</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure</measure>
    <time_frame>Baseline, Post-Intervention (&lt;2 Hours)</time_frame>
    <description>Measured at rest and during exercise</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure</measure>
    <time_frame>Baseline, Post-Intervention (&lt;2 Hours)</time_frame>
    <description>Measured at rest and during exercise</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceived Exertion</measure>
    <time_frame>Baseline, Post-Intervention (&lt;2 Hours)</time_frame>
    <description>Measured during exercise</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen Consumption</measure>
    <time_frame>Baseline, Post-Intervention (&lt;2 Hours)</time_frame>
    <description>Measure of metabolic activity</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Cannabis</condition>
  <condition>Cardiovascular Risk Factor</condition>
  <arm_group>
    <arm_group_label>High THC, Smoked</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High THC, Vaporized</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High CBD, Smoked</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High CBD, Vaporized</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabis</intervention_name>
    <description>Cannabis of (~10% THC concentration &lt;1% CBD concentration) will be smoked.</description>
    <arm_group_label>High THC, Smoked</arm_group_label>
    <other_name>High THC, Smoked</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabis</intervention_name>
    <description>Cannabis of (~10% THC concentration &lt;1% CBD concentration) will be vaporized.</description>
    <arm_group_label>High THC, Vaporized</arm_group_label>
    <other_name>High THC, Vaporized</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabis</intervention_name>
    <description>Cannabis of (~10% CBD concentration &lt;1% THC concentration) will be smoked.</description>
    <arm_group_label>High CBD, Smoked</arm_group_label>
    <other_name>High CBD, Smoked</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabis</intervention_name>
    <description>Cannabis of (~10% CBD concentration &lt;1% THC concentration) will be vaporized.</description>
    <arm_group_label>High CBD, Vaporized</arm_group_label>
    <other_name>High CBD, Vaporized</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of signed and dated informed consent form&#xD;
&#xD;
          2. Stated willingness to comply with all study procedures and availability for the&#xD;
             duration of the study&#xD;
&#xD;
          3. Male or female, aged 19-45yr&#xD;
&#xD;
          4. In good general health as evidenced by medical history and free of chronic disease&#xD;
&#xD;
          5. Must be experienced with cannabis use. This requires recreational cannabis use of a&#xD;
             minimum of once per week in the past 30 days as confirmed by urine test&#xD;
&#xD;
          6. Experience consuming cannabis recreationally by vaping dried cannabis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Deemed unfit to exercise by the PARQ+.&#xD;
&#xD;
          2. Current or past diagnoses of substance abuse disorder&#xD;
&#xD;
          3. Failure of recreational substance urine screening test&#xD;
&#xD;
          4. Current, past, or strong family history of psychosis, or has previously experienced a&#xD;
             cannabis-related psychotic episode&#xD;
&#xD;
          5. Current or past diagnoses of cannabis use disorder&#xD;
&#xD;
          6. Current or past diagnoses of any mood or anxiety disorder&#xD;
&#xD;
          7. Identified ECG abnormalities&#xD;
&#xD;
          8. Systolic blood pressure exceeding 160mmHg&#xD;
&#xD;
          9. Diastolic blood pressure exceeding 90mmHg&#xD;
&#xD;
         10. Resting heart rate exceeding 100bpm, or lower than 40bpm&#xD;
&#xD;
         11. Diagnosed with respiratory disease&#xD;
&#xD;
         12. Diagnosed with cardiovascular disease&#xD;
&#xD;
         13. Diagnosed with liver disease&#xD;
&#xD;
         14. Diagnosed with kidney disease&#xD;
&#xD;
         15. Is Pregnant or planning to be pregnant&#xD;
&#xD;
         16. Currently taking prescription medication (excluding contraceptive medication)&#xD;
&#xD;
         17. Is a cigarette smoker&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jamie F Burr, PhD</last_name>
    <phone>(519) 824-4120</phone>
    <phone_ext>52591</phone_ext>
    <email>burrj@uoguelph.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christian P Cheung, MSc</last_name>
    <phone>6472058535</phone>
    <email>ccheun05@uoguelph.ca</email>
  </overall_contact_backup>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 3, 2020</study_first_submitted>
  <study_first_submitted_qc>December 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2021</study_first_posted>
  <last_update_submitted>December 31, 2020</last_update_submitted>
  <last_update_submitted_qc>December 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Guelph</investigator_affiliation>
    <investigator_full_name>Jamie Burr</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 11, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/84/NCT04693884/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 16, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/84/NCT04693884/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

